[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597506":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":42,"responsibleParty":64,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":26,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Semaglutide + Combination NRT for up to 6 months",[13,14],"Drug: Semaglutide","Drug: Nicotine replacement",{"label":16,"type":17,"description":18,"interventionNames":19},"Control","ACTIVE_COMPARATOR","Combination NRT for up to 6 months",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Semaglutide","Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Nicotine replacement","Nicotine patch plus short-acting NRT gum or lozenge",[16,9],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Evyanne Quirouette","CONTACT","613-696-7000","17596","equirouette@ottawaheart.ca",{"name":39,"role":34,"phone":35,"phoneExt":40,"email":41},"Nidhi Agrawal","14355","NAgrawal@ottawaheart.ca",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of Ottawa Heart Institute","RECRUITING","Ottawa","Ontario","K1Y 4W7","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-75.69812,45.41117,{"lat":55,"lon":54},[58,61],{"name":59,"role":34,"phone":35,"phoneExt":26,"email":60},"Nidhi Agarwal","Nagrawal@ottawaheart.ca",{"name":62,"role":63,"phone":26,"phoneExt":26,"email":26},"Hassan Mir, MD","PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100597506","phase-3-semaglutide-for-smoking-cessation-in-patients-with-diabetes-100597506",false,"NCT07059377","Semaglutide for Smoking Cessation in Patients With Diabetes","Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial","GLP1-SC","Inclusion Criteria:\n\n* Adults (18 years or older) with type 2 diabetes\n* Currently residing in Ontario\n* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months\n* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.\n* Have not used GLP-1 receptor agonists in the past six months.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Contraindication to NRT or GLP-1 RA.\n* Current daily use of NRT or a GLP1 RA.\n* Use of bupropion, cytisine, and varenicline within the last 7 days.\n* Use of a DPP-IV inhibitor within the last 7 days.\n* Initiation of a new diabetes medication within the last 3 months.\n* As per the product monograph, participants with the following diagnoses or disorders will be excluded;\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia syndrome type 2\n* Diabetic ketoacidosis\n* Type I diabetes\n* Acute pancreatitis or pancreatic cancer\n* Acute, chronic or end-stage renal failure\n* Tachyarrhythmias\n* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).\n* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).","ALL","18 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.",[84,85,86],"Diabetes Mellitus, Type 2","Nicotine Addiction","Tobacco Dependence","2026-05-05",{"date":89,"type":90},"2026-05-11","ACTUAL",{"date":92,"type":90},"2026-02-13",{"date":94,"type":78},"2027-07",{"name":5,"class":6},1]